down arrow

Milestone Pharmaceuticals, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA59935V1076
USD
2.64
-0.01 (-0.38%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

2.582.66

52 Week

0.632.77
Valuation
Technical
Day's Volume

CASH

3.49 M

Shareholding (Mar 2025)

FII

1.44%

Held by 17 FIIs

DII

90.91%

Held by 5 DIIs

Promoter

5.49%

How big is Milestone Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Milestone Pharmaceuticals, Inc. has a market capitalization of 92.49 million, with net sales of 0.00 million and a net profit of -51.92 million over the last four quarters. The company's shareholder's funds are 13.15 million, and total assets are 75.50 million.

Market Cap: As of Jun 18, Milestone Pharmaceuticals, Inc. has a market capitalization of 92.49 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Milestone Pharmaceuticals reported net sales of 0.00 million and a net profit of -51.92 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 13.15 million, while total assets were reported at 75.50 million.

Read More

What does Milestone Pharmaceuticals, Inc. do?

22-Jun-2025

Milestone Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing etripamil for cardiovascular treatments. As of March 2025, it has a market cap of $92.49 million and reported a net profit loss of $21 million.

Overview: <BR>Milestone Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing etripamil for the treatment of cardiovascular indications within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -21 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 92.49 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.18 <BR>Return on Equity: 848.05% <BR>Price to Book: -15.11<BR><BR>Contact Details: <BR>Address: 1111 Dr.-Frederik-Philips Blvd Suite 420, SAINT-LAURENT QC: H4M 2X6 <BR>Tel: 1 514 3360444 <BR>Website: https://www.milestonepharma.com

Read More

Is Milestone Pharmaceuticals, Inc. overvalued or undervalued?

25-Jun-2025

As of May 13, 2024, Milestone Pharmaceuticals, Inc. is considered overvalued and has been downgraded to "does not qualify" due to negative financial metrics, including a Price to Book Value of -15.11 and a year-to-date return of -25.42%, significantly underperforming compared to the S&P 500.

As of 13 May 2024, the valuation grade for Milestone Pharmaceuticals, Inc. has moved from risky to does not qualify, indicating a significant downgrade in its investment appeal. The company is currently considered overvalued, reflected by its negative Price to Book Value of -15.11 and EV to EBITDA of -1.76. Additionally, the ROE is negative due to a lack of positive book value, further emphasizing the company's financial struggles.<BR><BR>In comparison to its peers, Milestone's EV to EBIT ratio of -1.74 stands out against Eton Pharmaceuticals, Inc. with a ratio of -92.8956, and Abeona Therapeutics, Inc. at -4.5154, both of which are also classified as risky. The stark negative ratios across the board suggest that the company is not generating value relative to its peers. Despite a recent uptick in stock price, Milestone's year-to-date return of -25.42% compared to the S&P 500's 2.44% reinforces the notion that it is not a favorable investment at this time.

Read More

Is Milestone Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of September 10, 2025, Milestone Pharmaceuticals, Inc. shows a bullish technical trend with strong weekly indicators, despite mixed signals on daily and monthly timeframes, and has outperformed the S&P 500 recently, although it has underperformed over longer periods.

As of 10 September 2025, the technical trend for Milestone Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. Bollinger Bands indicate a bullish stance on the monthly timeframe and mildly bullish on the weekly. However, daily moving averages are mildly bearish, and the KST shows a mixed picture with weekly mildly bearish and monthly mildly bullish signals. The Dow Theory reflects a mildly bullish weekly trend but a mildly bearish monthly trend. <BR><BR>In terms of performance, the stock has outperformed the S&P 500 over the past week and month, with returns of 2.09% and 14.71% compared to 1.05% and 2.33% for the index, respectively. However, it has significantly underperformed over longer periods, particularly in the 3-year and 5-year comparisons. Overall, the current technical stance is bullish, supported by strong weekly indicators despite some mixed signals in other timeframes.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 149 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.70

stock-summary
Return on Equity

312.93%

stock-summary
Price to Book

-8.38

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-13 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
48.31%
0%
48.31%
6 Months
56.21%
0%
56.21%
1 Year
41.94%
0%
41.94%
2 Years
-16.72%
0%
-16.72%
3 Years
-46.56%
0%
-46.56%
4 Years
-54.79%
0%
-54.79%
5 Years
-60.6%
0%
-60.6%

Milestone Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Milestone Pharmaceuticals, Inc. technically bullish or bearish?

As of 10 September 2025, the technical trend for Milestone Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. Bollinger Bands indicate a bullish stance on the monthly timeframe and mildly bullish on the weekly. However, daily moving averages are mildly bearish, and the KST shows a mixed picture with weekly mildly bearish and monthly mildly bullish signals. The Dow Theory reflects a mildly bullish weekly trend but a mildly bearish monthly trend. In terms of performance, the stock has outperformed the S&P 500 over the past week and month, with returns of 2.09% and 14.71% compared to 1.05% and 2.33% for the index, respectively. However, it has significantly underperformed over longer periods, particularly in the 3-year and 5-year comparisons. Overall, the current technical stance is bullish, supported by strong weekly indica...

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
2.30%
EBIT to Interest (avg)
-36.88
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.18
Sales to Capital Employed (avg)
0.05
Tax Ratio
0.54%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
49.56%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-15.11
EV to EBIT
-1.74
EV to EBITDA
-1.76
EV to Capital Employed
-12.60
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 4 Schemes (2.17%)

Foreign Institutions

Held by 17 Foreign Institutions (1.44%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 37.50% vs -67.74% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-12.60",
          "val2": "-20.60",
          "chgp": "38.83%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.00",
          "val2": "0.90",
          "chgp": "11.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-13.00",
          "val2": "-20.80",
          "chgp": "37.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs -80.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 30.49% vs -2.23% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "1.00",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-41.70",
          "val2": "-60.80",
          "chgp": "31.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.60",
          "val2": "2.60",
          "chgp": "38.46%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-41.50",
          "val2": "-59.70",
          "chgp": "30.49%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-61,410.00%",
          "chgp": "6,141.00%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-12.60
-20.60
38.83%
Interest
1.00
0.90
11.11%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-13.00
-20.80
37.50%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 37.50% vs -67.74% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
1.00
-100.00%
Operating Profit (PBDIT) excl Other Income
-41.70
-60.80
31.41%
Interest
3.60
2.60
38.46%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-41.50
-59.70
30.49%
Operating Profit Margin (Excl OI)
0.00%
-61,410.00%
6,141.00%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs -80.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 30.49% vs -2.23% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Milestone Pharmaceuticals, Inc. stock-summary
stock-summary
Milestone Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
Milestone Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is its short-acting calcium channel blocker. It is developing Etripamil as a nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia (PSVT), as they occur. It is also focused on developing treatments for other indications, such as Atrial Fibrillation and Angina. Etripamil is in Phase-III development for PSVT.
Company Coordinates stock-summary
Company Details
1111 Dr.-Frederik-Philips Blvd Suite 420 , SAINT-LAURENT QC : H4M 2X6
stock-summary
Tel: 1 514 3360444
stock-summary
https://www.milestonepharma.com
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."